Harpoon Therapeutics, Inc. (NASDAQ:HARP) Receives $32.17 Average Target Price from Brokerages

Posted by on Sep 25th, 2023

Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $32.17.

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group cut their price target on Harpoon Therapeutics from $80.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, September 14th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Harpoon Therapeutics in a research note on Thursday, August 10th. Finally, Citigroup cut their price target on Harpoon Therapeutics from $60.00 to $33.00 and set a “buy” rating for the company in a research note on Monday, September 18th.

Get Our Latest Research Report on HARP

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Delphia USA Inc. bought a new position in shares of Harpoon Therapeutics during the 1st quarter valued at about $57,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Harpoon Therapeutics by 571.5% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 12,986 shares of the company’s stock valued at $25,000 after acquiring an additional 11,052 shares during the last quarter. Sequoia Financial Advisors LLC bought a new position in shares of Harpoon Therapeutics in the 1st quarter valued at about $66,000. Two Sigma Investments LP lifted its holdings in shares of Harpoon Therapeutics by 73.6% in the 3rd quarter. Two Sigma Investments LP now owns 33,361 shares of the company’s stock valued at $32,000 after acquiring an additional 14,149 shares during the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of Harpoon Therapeutics in the 1st quarter valued at about $32,000. Institutional investors own 74.01% of the company’s stock.

Harpoon Therapeutics Stock Performance

HARP stock opened at $4.00 on Friday. The business’s 50 day moving average price is $7.67 and its two-hundred day moving average price is $7.26. Harpoon Therapeutics has a fifty-two week low of $3.96 and a fifty-two week high of $33.55. The company has a market capitalization of $15.52 million, a price-to-earnings ratio of -0.34 and a beta of 1.48.

Harpoon Therapeutics (NASDAQ:HARP – Get Free Report) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of ($4.30) by $4.60. Harpoon Therapeutics had a negative return on equity of 620.00% and a negative net margin of 86.73%. The firm had revenue of $20.22 million for the quarter, compared to analysts’ expectations of $9.19 million. Sell-side analysts forecast that Harpoon Therapeutics will post -5.83 earnings per share for the current year.

About Harpoon Therapeutics

(Get Free Report

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.

Read More

Analyst Recommendations for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.